Intervention 1 for Epilepsy

Phase 1

Waitlist Available

Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 days

Summary

This trial is testing a new drug called OPC-214870 to help people with epilepsy who do not get better with current medications. The drug works by affecting certain brain pathways to reduce seizures.

Eligible Conditions

Epilepsy

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in Standardized Photosensitivity Range (SPR)

Secondary study objectives

Onset and duration of SPR

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Intervention 1Experimental Treatment2 Interventions

Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.

Group II: PlaceboPlacebo Group2 Interventions

Single dose; potential for a matching OPC-214870 dose to be administered.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

OPC-214870

2020

Completed Phase 1

~20

Do I qualify?Apply below to find out